Technetium (99mTc) tetrofosmin is administered in low dose and the therapeutic plasma concentration is considered to be insignificant in relation to having potentially porphyrinogenic effects.

After administration, technetium (99mTc) tetrofosmin is rapidly distributed and has a high affinity for myocardial and skeletal muscle (Higley 1993). According to Schreuder and coworkers, the plasma concentration of technetium (99mTc) tetrofosmin is 0.07µM and the hepatic load is therefore probably insignificant (Shcreuder 2016). Approximately 66% of the injected activity is excreted within 48 hours post-injection, with approximately 40% excreted in the urine and 26% in the feces (FDA label). No dug-drug interactions are listed in interaction databases (Lexicomp, Micromedex).